A Texas-based phar­ma has en­list­ed Catal­ent for oral sol­id man­u­fac­tur­ing; Cy­ti­va drops mas­sive man­u­fac­tur­ing in­vest­ment in home state

CD­MO Catal­ent has kept busy with merg­ers and ac­qui­si­tions, but Mon­day, it an­nounced a col­lab­o­ra­tion with Dis­per­Sol to ac­cel­er­ate the man­u­fac­tur­ing of the com­pa­ny’s on­col­o­gy drugs.

Catal­ent will in­stall a com­mer­cial-scale Kineti­Sol line at the oral solids de­vel­op­ment and man­u­fac­tur­ing fa­cil­i­ty in Som­er­set, NJ. The plat­form works to turn mol­e­cules with clin­i­cal promise in­to vi­able med­i­cines, and the Kineti­Sol tech­nol­o­gy will be used for all of Dis­per­Sol’s pipeline prod­ucts. That in­cludes a Phase III tri­al for iron over­load dis­or­der and a Phase II tri­al against prostate can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER